在SOD1-和TDP-43-相关的ALS中蛋白质聚合和治疗策略
Maria Tsekrekou1, Maria Giannakou1,2, Katerina Papanikolopoulou3,4
1Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece.
Frontiers in molecular biosciences
|June 10, 2024
概括
肌缩侧面硬化症 (ALS) 涉及有毒的蛋白质聚合物. 用新的小分子和来准错误折叠的SOD1和TDP-43,为ALS治疗提供了有前途的治疗策略.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 分子病理学分子病理学
- 药物发现 药物发现
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病.
- 病理性ALS是由错误折叠的蛋白质的细胞质内含的特征.
- 目前的ALS治疗提供有限的临床益处.
研究的目的:
- 审查错误折叠的蛋白质在ALS发病过程中的作用.
- 突出针对错误折叠的蛋白质的治疗策略.
- 讨论用于ALS治疗的新型小分子和.
主要方法:
- 综合文献综述. 这是一个全面的文献综述.
- 对ALS中蛋白质聚合机制的分析.
- 对向SOD1和TDP-43的小分子和的评估.
主要成果:
- 错误折叠的Cu/Zn超氧化物脱酶 (SOD1) 和TARDNA结合蛋白43 (TDP-43) 是ALS的关键.
- 小分子和具有抑制SOD1和TDP-43聚合的潜力.
- 这些药物可能会改变疾病的进展.
结论:
- 针对错误折叠的蛋白质是ALS的关键治疗方法.
- 新型的小分子和代表了ALS治疗的有希望的途径.
- 需要进一步的研究来开发有效的ALS治疗方法.
更多相关视频
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Parkinson's Disease: Overview
527
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
527


